Christine De Bruyn1,2, Thaïs Baert1,3, Thierry Van den Bosch1,4, An Coosemans5,6. 1. Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. 2. Department of Obstetrics and Gynecology, University Hospital Antwerp, Edegem, Belgium. 3. Department of Gynecology and Gynecologic Oncology, Kliniken Essen Mitte (KEM), Essen, Germany. 4. Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. 5. Department of Oncology, Laboratory of Tumor Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. an.coosemans@kuleuven.be. 6. Department of Obstetrics and Gynecology, University Hospitals Leuven, Leuven, Belgium. an.coosemans@kuleuven.be.
Abstract
PURPOSE OF REVIEW: Uterine cancer comprises endometrial carcinoma and the uterine sarcoma. Endometrial carcinomas are the most frequent variant and have early symptoms and a solid diagnostic work up, resulting in a rather fair prognosis. However, in case of advanced stage disease and relapse, treatment options are limited and prognosis is impaired. Uterine sarcomas are rare, often lacking symptoms and no diagnostic tool for correct pre-operative diagnosis are available. Prognosis is poor. RECENT FINDINGS: Circulating biomarkers as a liquid biopsy could be beneficial as a diagnostic tool in uterine sarcomas. For both carcinomas and sarcomas, circulating biomarkers could be of use in predicting early disease recurrence. This review in endometrial carcinoma and uterine sarcoma focus on circulating biomarkers; such as proteins; circulating tumor cells; circulating tumor DNA; microRNA; and immune cells.
PURPOSE OF REVIEW: Uterine cancer comprises endometrial carcinoma and the uterine sarcoma. Endometrial carcinomas are the most frequent variant and have early symptoms and a solid diagnostic work up, resulting in a rather fair prognosis. However, in case of advanced stage disease and relapse, treatment options are limited and prognosis is impaired. Uterine sarcomas are rare, often lacking symptoms and no diagnostic tool for correct pre-operative diagnosis are available. Prognosis is poor. RECENT FINDINGS: Circulating biomarkers as a liquid biopsy could be beneficial as a diagnostic tool in uterine sarcomas. For both carcinomas and sarcomas, circulating biomarkers could be of use in predicting early disease recurrence. This review in endometrial carcinoma and uterine sarcoma focus on circulating biomarkers; such as proteins; circulating tumor cells; circulating tumor DNA; microRNA; and immune cells.
Authors: Gloria S Huang; Lydia G Chiu; Juliana S Gebb; Marc J Gunter; Paniti Sukumvanich; Gary L Goldberg; Mark H Einstein Journal: Gynecol Oncol Date: 2007-10-23 Impact factor: 5.482
Authors: Nicole Brooks; Lily Stojanovska; Peter Grant; Vasso Apostolopoulos; Christine F McDonald; Dodie S Pouniotis Journal: Int J Gynecol Cancer Date: 2012-11 Impact factor: 3.437
Authors: Brad H Nelson; Jessica N McAlpine; Aline Talhouk; Heather Derocher; Pascal Schmidt; Samuel Leung; Katy Milne; C Blake Gilks; Michael S Anglesio Journal: Clin Cancer Res Date: 2018-12-06 Impact factor: 12.531
Authors: M A C Versluis; S Marchal; A Plat; G H de Bock; T van Hall; M de Bruyn; H Hollema; H W Nijman Journal: Eur J Cancer Date: 2017-10-20 Impact factor: 9.162
Authors: Nicholas C Eastley; Barbara Ottolini; Rita Neumann; Jin-Li Luo; Robert K Hastings; Imran Khan; David A Moore; Claire P Esler; Jacqueline A Shaw; Nicola J Royle; Robert U Ashford Journal: Oncotarget Date: 2018-01-19
Authors: Lorena Alonso-Alconada; Laura Muinelo-Romay; Kadri Madissoo; Antonio Diaz-Lopez; Camilla Krakstad; Jone Trovik; Elisabeth Wik; Dharani Hapangama; Lieve Coenegrachts; Amparo Cano; Antonio Gil-Moreno; Luis Chiva; Juan Cueva; Maria Vieito; Eugenia Ortega; Javier Mariscal; Eva Colas; Josep Castellvi; Maite Cusido; Xavier Dolcet; Hans W Nijman; Tjalling Bosse; John A Green; Andrea Romano; Jaume Reventos; Rafael Lopez-Lopez; Helga B Salvesen; Frederic Amant; Xavier Matias-Guiu; Gema Moreno-Bueno; Miguel Abal Journal: Mol Cancer Date: 2014-09-27 Impact factor: 27.401
Authors: Luca Cassetta; Stamatina Fragkogianni; Andrew H Sims; Agnieszka Swierczak; Lesley M Forrester; Hui Zhang; Daniel Y H Soong; Tiziana Cotechini; Pavana Anur; Elaine Y Lin; Antonella Fidanza; Martha Lopez-Yrigoyen; Michael R Millar; Alexandra Urman; Zhichao Ai; Paul T Spellman; E Shelley Hwang; J Michael Dixon; Lisa Wiechmann; Lisa M Coussens; Harriet O Smith; Jeffrey W Pollard Journal: Cancer Cell Date: 2019-03-28 Impact factor: 31.743
Authors: Kelechi Njoku; Amy E Campbell; Bethany Geary; Michelle L MacKintosh; Abigail E Derbyshire; Sarah J Kitson; Vanitha N Sivalingam; Andrew Pierce; Anthony D Whetton; Emma J Crosbie Journal: Cancers (Basel) Date: 2021-02-10 Impact factor: 6.575